Bharat Biotech submits additional data for Covaxin, WHO's approval likely on November 3

NH Bureau Wednesday, 03 November 2021 07:27:59 AM

Bharat Biotech submits additional data for Covaxin, WHO's approval likely on November 3 (Image: Screengrab from video tweeted by @WHO)

New Delhi : Bharat Biotech has submitted the additional data required for the crucial approval to Covaxin as a vaccine for coronavirus.

The World Health Organisation will meet on Wednesday for a final risk- benefit assessment for its Emergency use listing.

"The TAG met on October 26, 2021, and decided to seek additional clarifications from the Covaxin manufacturers that are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine." said a WHO official.

The Technical Advisory group had met October 26 and had sought additional details from Bharat Biotech. Covaxin has demonstrated 77.8 percent effectiveness against symptomatic Covid-19 and 65.2 percent protection against the new Delta variant. In June the company had said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech's Covaxin and AstraZeneca and Serum Institute's Covishield are the two widely used vaccines in India.